Previous Close | 0.2949 |
Open | 0.2840 |
Bid | 0.2701 x 1100 |
Ask | 0.2909 x 4000 |
Day's Range | 0.2770 - 0.2999 |
52 Week Range | 0.2030 - 5.6000 |
Volume | |
Avg. Volume | 1,485,626 |
Market Cap | 5.168M |
Beta (5Y Monthly) | 1.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.2020 |
Earnings Date | Nov 27, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today its annual financial results for the year ended December 31, 2021. Financial Highlights for Fiscal Year 2021 Total revenues were RMB18.0 million (US$2.8 million) in fiscal year 2021, a decrease of 12.3% from RMB20.5 million (US$3.1 million) in fiscal year 2020.Gross margin wa
PHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that The Nasdaq Stock Market LLC (“Nasdaq) has notified the Company on May 9, 2022, that ANPC’s American Depositary Shares are now in compliance with the maintenance of the minimum market value of publicly held shares (“MVPHS”) of $1,000,000
PHILADELPHIA, May 06, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Nasdaq Hearings Panel (the “Panel”) has granted the request of AnPac Bio to transfer the Company’s American Depositary Shares from The Nasdaq Global Market to The Nasdaq Capital Market, effective May 6, 2022 and to continue its listi